[October 20, 2016]

Global Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Pipeline Report 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals - Research and Markets

Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Pipeline Review, H2 2016" report to their offering.

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target (News - Alert) constitutes close to 11 molecules. Out of which approximately 3 molecules are developed by Companies and remaining by the Universities

Institutes. Our latest report Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2016, outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclersis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina). The molecules developed by Companies in Phase II and Preclinical stages are 2 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 7 molecules, respectively.

Furthermore, this report also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

1. Introduction
2. Plasminogen Activator Inhibitor 1 Overview
3. Therapeutics Development
4. Pipeline Products for Plasminogen Activator Inhibitor 1 - Overview
5. Pipeline Products for Plasminogen Activator Inhibitor 1 - Comparative Analysis
6. Plasminogen Activator Inhibitor 1 - Therapeutics under Development by Companies
7. Plasminogen Activator Inhibitor 1 - Therapeutics under Investigation by Universities/Institutes
8. Plasminogen Activator Inhibitor 1 Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Plasminogen Activator Inhibitor 1 - Products under Development by Companies
13. Plasminogen Activator Inhibitor 1 - Products under Investigation by Universities/Institutes
14. Plasminogen Activator Inhibitor 1 - Companies Involved in Therapeutics Development

• D-Pharm Ltd.
• Jazz Pharmaceuticals Plc

For more information about this report visit http://www.researchandmarkets.com/research/w8bwmm/plasminogen

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006382/en/

[ Back To TMCnet.com's Homepage ]